Compound 766
Identifiers
- Canonical SMILES:
CN1c2ncnn2[C@H](C2=C1c1ccccc1O[C@@H]2c1ccc(cc1)C#C)c1ccc(Br)cc1
- InChi:
InChI=1S/C27H19BrN4O/c1-3-17-8-10-19(11-9-17)26-23-24(18-12-14-20(28)15-13-18)32-27(29-16-30-32)31(2)25(23)21-6-4-5-7-22(21)33-26/h1,4-16,24,26H,2H3/t24-,26+/m0/s1
- InChiKey:
DHPJTVAVWJRWKL-AZGAKELHSA-N
External links
44549491 |
External search
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
MDM2-Like / P53 | 5.61 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 494.07 g/mol | |||
HBA | 5 | |||
HBD | 0 | |||
HBA + HBD | 5 | |||
AlogP | 5.89 | |||
TPSA | 43.18 | |||
RB | 2 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.4268 | BMS-394136 | DB12067 | |
0.3653 | GDC-0927 | DB14934 | |
0.3566 | LY-2881835 | DB15046 | |
0.3406 | Parsaclisib | DB14867 | |
0.3378 | Galicaftor | DB14894 | |
0.3354 | (4aS,6R,8aS)-11-[8-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)octyl]-6-hydroxy-3-methoxy-5,6,9,10-tetrahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-11-ium | DB02673 | |
0.3333 | Iclaprim | DB06358 | |
0.3333 | (S)-iclaprim | DB07938 | |
0.3333 | 5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl]methyl]pyrimidine-2,4-diamine | DB08741 | |
0.3316 | Naldemedine | DB11691 | |
0.3307 | Cannabichromene | DB14735 | |
0.3298 | Rocaglamide | DB15495 | |
0.3284 | MK-1775 | DB11740 | |
0.3275 | Tmr | DB03903 | |
0.3262 | Didesmethylrocaglamide | DB15496 |